Kinarus Therapeutics Holding AG (KNRS.SW)
- Previous Close
0.0034 - Open
0.0034 - Bid --
- Ask 0.0034 x --
- Day's Range
0.0030 - 0.0034 - 52 Week Range
0.0002 - 0.0132 - Volume
5,107,541 - Avg. Volume
11,316,595 - Market Cap (intraday)
4.419M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
107.00
Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of viral, respiratory, and ophthalmic diseases. Its therapeutic drug candidate is KIN001, an advanced clinical stage p38 mitogen-activated protein kinase inhibitor combined with a marketed drug together enabling an oral long-term treatment for patients suffering from diseases. The company was founded in 2017 and is based in Basel, Switzerland.
www.kinarus.comRecent News: KNRS.SW
Performance Overview: KNRS.SW
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KNRS.SW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KNRS.SW
Valuation Measures
Market Cap
4.42M
Enterprise Value
7.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.71
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.18
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
-0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Research Analysis: KNRS.SW
Analyst Price Targets
Fair Value
No Fair Value available for this ticker